SCHEMBL676805

SCHEMBL676805

COc1cc(-c2[o+]c3cc(O)cc(O)c3cc2OC2O[C@H](CO)[C@@H](O)[C@@H]2O)cc(OC)c1O

nearest known ligand 0.72

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CD38 P28907 4/20 0.72
DPP4 P27487 2/20 0.72
F2 P00734 1/20 0.64
MAOA P21397 1/20 0.57
TYR P14679 1/20 0.53
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
SLC28A3 Q9HAS3 2/20 0.48
ALDH1A1 P00352 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA13 Q8N1Q1 1/20 0.46
EPHX2 P34913 2/20 0.46
TSHR P16473 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oenin SCHEMBL29521448 0.99 CD38 (0.74) CD38DPP4F2MAOATYR
Oenin SCHEMBL676018 0.99 CD38 (0.74) CD38DPP4F2MAOATYR
Oenin SCHEMBL29468973 0.99 CD38 (0.74) CD38DPP4F2MAOATYR
Oenin SCHEMBL6139047 0.99 CD38 (0.74) CD38DPP4F2MAOATYR
Oenin SCHEMBL29894980 0.99 CD38 (0.74) CD38DPP4F2MAOATYR
Oenin SCHEMBL662772 0.99 CD38 (0.74) CD38DPP4F2MAOATYR
Oenin SCHEMBL723403 0.98 CD38 (0.73) CD38DPP4F2MAOATYR
Oenin SCHEMBL29881103 0.98 CD38 (0.73) CD38DPP4F2MAOATYR
Oenin SCHEMBL1096836 0.98 CD38 (0.73) CD38DPP4F2MAOATYR
SCHEMBL30901362 0.97 CD38 (0.75) CD38DPP4F2MAOATYR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118914413-B Ultra-high performance liquid chromatography-tandem mass spectrometry method for simultaneously detecting 39 kinds of anthocyanin in litchi 海南省农业科学院三亚研究院(海南省实验动物研究中心) 2024-12-03 CN claimed
CN-118914413-A Ultra-high performance liquid chromatography-tandem mass spectrometry method for simultaneously detecting 39 kinds of anthocyanin in litchi 海南省农业科学院三亚研究院(海南省实验动物研究中心) 2024-11-08 CN claimed
US-20240350574-A1 PHENOLIC PHYTOCHEMICALS FOR BONE METASTASIS OF CANCER NDSU RESEARCH FOUNDATION 2024-10-24 US claimed
CN-116870046-B Use of natural compounds and derivatives thereof for the treatment of arterial lesions 中国科学院上海药物研究所 2024-09-20 CN claimed
CN-118382694-A Methods and compositions for generating human erythroid progenitors 特雷尔赫德生物系统股份有限公司 2024-07-23 CN claimed
WO-2023219526-A1 MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT PROKIN MILAN (RS) 2023-11-16 WO claimed
CN-116870046-A Use of natural compounds and derivatives thereof for the treatment of arterial lesions 中国科学院上海药物研究所 2023-10-13 CN claimed
CN-116660543-A Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof 中国人民解放军陆军军医大学第一附属医院 2023-08-29 CN claimed
US-11712056-B2 Extract obtained from several plants for use in the prevention and/or treatment of chronic inflammatory bowel diseases VALBIOTIS (FR) 2023-08-01 US claimed
EP-3982924-B1 PLANT EXTRACT MIXTURE FOR USE IN THE PREVENTION AND/OR TREATMENT OF CHRONIC INFLAMMATORY BOWEL DISEASES VALBIOTIS (FR) 2023-07-26 EP claimed
US-10232005-B2 Compositions and methods for controlling carbohydrate and fat metabolism UNIVERSITE CLERMONT AUVERGNE (FR) 2019-03-19 US claimed
US-9962420-B2 Compositions and methods for treating diabetes, fatty liver, cardiopathies, insulin resistance, carbohydrate and fat metabolism VALBIOTIS (FR) 2018-05-08 US claimed
US-20170028004-A1 COMPOSITIONS AND METHODS FOR CONTROLING CARBOHYDRATE AND FAT METABOLISM UNIVERSITE CLERMONT AUVERGNE (FR) 2017-02-02 US claimed
US-20160106793-A1 COMPOSITIONS AND METHODS FOR CONTROLING CARBOHYDRATE AND FAT METABOLISM UNIVERSITE CLERMONT AUVERGNE (FR) 2016-04-21 US claimed
EP-2976061-A1 COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS Dentalmed Pharm Holding Ltd. (BE) 2016-01-27 EP claimed
WO-2014147613-A1 COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS DENTALMED PHARM HOLDING LTD. (BE) 2014-09-25 WO claimed
US-20090176718-A1 Berry Preparations For Treatment Of Diabetes And Metabolic Syndrome NIH - DEITR 2009-07-09 US claimed
WO-2009059218-A1 BERRY PREPARATIONS FOR TREATMENT OF DIABETES AND METABOLIC SYNDROME PHYTOMEDICS, INC. (US) 2009-05-07 WO claimed
US-20020054924-A1 Novel compositions derived from cranberry and grapefruit and therapeutic uses therefor LEAHY MARGARET M (US) 2002-05-09 US claimed
WO-2001080870-A2 COMPOSITIONS DERIVED FROM CRANBERRY AND GRAPEFRUIT AND THERAPEUTIC USES THEREFOR OCEAN SPRAY CRANBERRIES, INC. (US) 2001-11-01 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10232005-B2 Compositions and methods for controlling carbohydrate and fat metabolism PLIN3, GYS1, PCK1 CD38 331/4885DPP4 1479/4885F2 1244/4885
US-20160106793-A1 COMPOSITIONS AND METHODS FOR CONTROLING CARBOHYDRATE AND FAT METABOLISM PLIN3, GYS1, PLIN5 CD38 348/4885DPP4 1009/4885F2 1238/4885
US-20090176718-A1 Berry Preparations For Treatment Of Diabetes And Metabolic Syndrome GPR119, FABP4, GYS2 CD38 740/4885DPP4 109/4885F2 1393/4885
US-20170028004-A1 COMPOSITIONS AND METHODS FOR CONTROLING CARBOHYDRATE AND FAT METABOLISM PLIN3, GYS1, PLIN5 CD38 348/4885DPP4 1009/4885F2 1238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.